Epizyme 8-K Shows Co. Received Written Notice From Glaxo Group GSK Elected To Terminate Collab, License Deal With Epizyme
On December 16, 2021, Epizyme, Inc. (the “Company”) received written notice from Glaxo Group Limited (“GSK”) that GSK has elected to terminate the Collaboration and License Agreement dated
Epizyme’s Return On Capital Employed Insights
Benzinga Pro data, Epizyme (NASDAQ:EPZM) reported Q3 sales of $5.20 million. Earnings fell to a loss of $64.16 million, resulting in a 10.09% decrease from last quarter.
The Daily Biotech Pulse: Double Dose Of Positive Tidings For Merck, Alkermes Slips On Partial Termination Of J&J Licensing Deal, Amgen Migraine Drug Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
Epizyme Q3 EPS $(0.64) Misses $(0.48) Estimate
Epizyme (NASDAQ:EPZM) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.48) by 33.33 percent. This is a 16.36 percent decrease over losses of $(0.55) per share from the
Earnings Scheduled For November 9, 2021
Companies Reporting Before The Bell
• Imara (NASDAQ:IMRA) is projected to report earnings for its third quarter.
• KT (NYSE:KT) is projected to report earnings for its third quarter.